HENDERSON, Nev. (TheStreet) -- I held out hope Spectrum Pharmaceuticals' new COO Ken Keller, formerly of Amgen , would bring a positive change of direction to the company, reversing the downward slide caused by current CEO Raj Shrotriya. Sadly, I'm still seeing business as usual at Spectrum, which is no good for investors. On Thursday, Allergan returned rights to the bladder cancer drug apaziquone back to Spectrum. The move isn't a surprise given the failure of two phase III studies. Bad news, except in the alternative reality where Spectrum and its diehard supporters reside. There, ... Read More